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Background. The genetic contribution to longevity in humans has been estimated to range from 15% to 25%. Only 
two genes, APOE and FOXO3, have shown association with longevity in multiple independent studies.
Methods. We conducted a meta-analysis of genome-wide association studies including 6,036 longevity cases, age 
≥90 years, and 3,757 controls that died between ages 55 and 80 years. We additionally attempted to replicate earlier 
identified single nucleotide polymorphism (SNP) associations with longevity.
Results. In our meta-analysis, we found suggestive evidence for the association of SNPs near CADM2 (odds ratio 
[OR] = 0.81; p value = 9.66 × 10−7) and GRIK2 (odds ratio = 1.24; p value = 5.09 × 10−8) with longevity. When attempt-
ing to replicate findings earlier identified in genome-wide association studies, only the APOE locus consistently rep-
licated. In an additional look-up of the candidate gene FOXO3, we found that an earlier identified variant shows a 
highly significant association with longevity when including published data with our meta-analysis (odds ratio = 1.17; 
p value = 1.85 × 10−10).
Conclusions. We did not identify new genome-wide significant associations with longevity and did not replicate 
earlier findings except for APOE and FOXO3. Our inability to find new associations with survival to ages ≥90 years 
because longevity represents multiple complex traits with heterogeneous genetic underpinnings, or alternatively, that 
longevity may be regulated by rare variants that are not captured by standard genome-wide genotyping and imputation 
of common variants.
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THERE is ample evidence that genetic factors are involved in extreme longevity both in humans and 
in other organisms. In model organisms, ranging from 
Caenorhabditis elegans to Mus musculus, mutations in the 
insulin/IGF-1 signaling (IIS) pathway have been shown 
to substantially increase lifespan (1–6). Other suggested 
mechanisms involve stress resistance as mediated by heat 
shock proteins (7,8), cellular senescence as mediated by tel-
omere length (9) and inflammation/immune function (10). 
The genetic contribution to longevity in humans has been 
estimated to range from 15% to 25% (11–13).
Although many human candidate longevity genes have been 
investigated, only two genes have been widely replicated. The 
first consistent association reported was APOE (14). It was 
subsequently replicated in both candidate gene and genome-
wide association studies (GWAS) with genome-wide signifi-
cant evidence (15–20). The second longevity gene, identified 
in American male centenarians of Japanese descent and repli-
cated in other candidate gene studies that included both men 
and women across ethnicities, was FOXO3, although this 
gene was not identified in GWAS (21–25).
Early GWAS have failed to identify novel longev-
ity genes as reviewed by Murabito and coworkers (26). 
In 2010, the Cohorts for Heart and Aging Research in 
Genomic Epidemiology (CHARGE) consortium published 
a meta-analysis of 1,836 longevity (90+) cases and a com-
parison group of 1,955 individuals who died between 55 
and 80 years of age (27). A total of 24 independent SNPs 
were identified, though none reached genome-wide signifi-
cance. Finally, a recent GWAS by Deelen and coworkers 
identified one new longevity locus on 5q33.3 (28).
The key to success to GWAS has proven to be large sam-
ple sizes. Since the original CHARGE longevity GWAS 
(27) additional members of each cohort have reached or 
exceeded age of 90 years and additional studies have joined 
the consortium, permitting an expanded meta-analysis of 
longevity. Using the much expanded sample of 6,036 lon-
gevity cases and 3,757 controls and the same study design 
as the original CHARGE longevity study, we attempted to 
produce robust new associations and replicate earlier identi-
fied associations for longevity coming from several earlier 
studies.
Methods
Participants
The participants in our study were of European ances-
try and included cohorts from the CHARGE Consortium 
(29). All cohorts periodically assess the vital status of their 
participants. Although some of the cohorts include multi-
ple ethnic groups, only data from Caucasian participants 
were used. Informed written consent was obtained from all 
participants, and appropriate institutional approvals were 
obtained. A brief description of each population is given in 
the Supplementary Material.
Longevity Phenotype
Longevity was defined as reaching age ≥90 years. A more 
extreme longevity threshold of age 100 years was consid-
ered. However, the sample size was deemed insufficiently 
powered. Genotyped participants who died between the 
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ages of 55 and 80 years were used as the control group. The 
control group was limited to deceased participants to ensure 
that no control individuals could subsequently achieve 
longevity. The minimum age at death was set to match 
the minimum age at enrollment in the Rotterdam Study. 
The maximal age at death was set arbitrarily at the age of 
80 years to include the majority of deaths and to exclude 
those participants who survived far beyond the average life 
expectancy for their respective birth cohort. Across the dis-
covery cohorts, there were 6,036 participants who achieved 
longevity and the control group had 3,757 participants.
We did not have direct replication cohorts; however, we 
performed a look-up of our strongest associations in three 
independent studies with similar phenotypes, one of which 
is a published GWAS on longevity (30).
Genotyping and Imputation
As different genotyping platforms were used across stud-
ies, we imputed to ~2.5 million SNPs using the HapMap 22 
CEU (Build 36) genotyped samples as a reference. Details 
on the study-specific quality control procedures for geno-
typing and imputation are found in Supplementary Table 1. 
Although genotyping between different studies was per-
formed on different genotyping platforms, genotyping of 
cases and controls within studies was performed on the 
same genotyping platform in each study.
Statistical Analysis
We used logistic regression to test each SNP for asso-
ciation with longevity using an additive model adjusting 
for sex and principal components to adjust for population 
stratification. Fixed-effects inverse-variance meta-analysis 
was performed using METAL. The p values were corrected 
for genomic control. Associations with a p value < 5 × 10−8 
were considered genome-wide significant, whereas associa-
tions with a p value < 1 × 10−5 were considered suggestive 
and taken forward to the look-up phase.
Detailed analysis of cohorts participating in the look-
up phase and additional analyses can be found in the 
Supplementary Material. Conditional analysis of the 
FOXO3 locus was performed using the GCTA tool which 
analyzes aggregate, not individual level data (31,32). We 
further attempted to replicate earlier identified SNP associ-
ations with longevity. Finally, we used gene networks avail-
able at www.genenetworks.nl as a bioinformatics resource 
to further investigate significant findings.
Results
General characteristics of discovery and look-up cohorts 
are found in Tables 1 and 2, respectively. Between 0.0% 
and 70.3%, varying per cohort, of those achieving longev-
ity were still alive at the time that longevity status was 
ascertained. Among those who had died, the distribution of 
causes of death differed between longevity cases and the 
comparison group. While 1.0%–17.3% of those achieving 
longevity died of cancer, 10.1%–50.3% of deaths in the 
control group could be attributed to cancer.
None of the SNP-longevity associations reached the 
genome-wide significance threshold of 5 × 10−8 in the 
discovery phase (Supplementary Figure  1), although 
the strongest association was borderline significant 
for rs1416280 located 369 kb from GRIK2 (odds ratio 
[OR]  =  1.24; p value  =  5.09 ×10−8). In total, seven loci 
passed the threshold for suggestive association (<1 × 10−5) 
and were included in the look-up phase (Table 3). For look-
up, we also included the most significant SNP in the current 
study from the known candidate longevity gene, FOXO3 
(p value = 8.56 × 10−5). Forest plots of all eight SNPs can 
be found in Supplementary Figure 2. Although none of the 
SNPs reached Bonferroni adjusted significance in any of 
the look-up cohorts, consistent results considering direction 
of effect were found for FOXO3 across discovery and look-
up cohorts (Table 3). Association results for CADM2 and, 
to a lesser degree, GRIK2 were consistent across cohorts. 
In pathway analysis using the gene networks tool, both 
CADM2 and GRIK2 genes were found to be involved in 
neuronal pathways (Supplementary Table 2).
Of the 24 SNPs identified as suggestively associated in 
the original CHARGE longevity GWAS (27), the p value 
for only one of these (GRIK2; rs954551) improved in the 
current study (Supplementary Table  3). One additional 
region (RGS7) from the earlier study appeared among the 
strongest associations in the current study, but the associa-
tion was not strengthened in the look-up phase of this study.
Next, we aimed to replicate the GWAS of Sebastiani 
and coworkers conducted on centenarians (Supplementary 
Table  4) (20). Two hundred and eighty-one SNPs were 
reported using four different genetic models (20). Six out 
of the 281 SNPs were reported to have a p value <1 × 10−5 
in the additive model. We attempted to replicate these six 
SNPs, and only the SNP at the APOE locus replicated at 
the Bonferroni corrected significance level (OR  =  1.20; 
p value = 4.8 × 10−4). Similarly, of the four regions iden-
tified with linkage analysis of longevity sib-pairs (age 
≥90 years ) (33) we also replicated only the APOE locus 
(Supplementary Table 5).
Finally, in a candidate gene approach, we examined the 
original SNP reported for the FOXO3 gene (rs2802292) in 
the current study and added our current study (each discov-
ery cohort individually) to the published studies reporting on 
the same FOXO3 SNP (Supplementary Table 6) (21–25,30). 
In the current study, rs2802292 reached a p value of .012 
(OR = 1.09). When including the published studies, both 
candidate gene and GWAS, in the meta-analysis rs2802292 
reached a p value of 1.85 × 10−10 (OR = 1.17). The Linkage 
Disequilibrium (LD) as measured by r2 between this SNP 
and the top FOXO3 SNP in the current study (rs10457180) 
was .64. In conditional analyses of the discovery phase 
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cohorts, including both SNPs, only rs10457180 remained 
significant at nominal p value (OR = 0.94; p value = 5.53 
× 10−4).
Discussion
In this investigation of 6,036 longevity cases and 3,757 
controls, we found suggestive evidence for the involvement 
of SNPs near CADM2 and GRIK2. We further confirmed 
the associations of APOE and FOXO3 with longevity.
FOXO3 is a known candidate gene for longevity and 
part of the well-characterized IIS pathway (6). Although 
originally identified in candidate gene studies, it did not 
earlier reach genome-wide significance (21–25). In this 
study, the strongest signal in the FOXO3 gene was found 
for rs10457180 which is in LD (r2 =  .64) with the earlier 
identified SNP rs2802292. Pooling our data with that of 
independent studies from literature yielded a p value of 
1.85 × 10−10. Although we included all studies reporting on 
FOXO3 association with longevity from the literature as 
well as contacted authors of earlier published GWAS for 
information on FOXO3 in their study (19), publication bias, 
which is common in candidate gene studies, may be influ-
encing the results of this analysis. In a conditional analysis 
of the discovery phase cohorts, only rs10457180 remained 
significant, which suggests that rs10457180 may be a better 
tagging SNP for the true causal variant. A point of notice 
is that FOXO3 has 99% sequence homology in its exonic 
regions with its pseudogene (ZNF286B), which could 
complicate the calling of genetic variants for this gene 
(34,35). However, the investigated variants (rs2802292 and 
Table 2. General Characteristics of Look-Up Cohorts
NECS LLFS EU_longevity
Cases (100+) Comparison Survival Analysis Cases (90+); Comparison (<65)
N 801 914 4,567 5,409; 16,121
Age at DNA draw (median [range]) 104 (95–119) 73 (54–90) 67 (25–110) NA
Follow-up (median [range]) NA 3 (0–7) NA
Women, % 72.0 56.0 55.0 NA
Alive, % 3.0 0.0 83.0 NA
Notes: LLFS = Long Life Family Study; NECS = New England Centenarian Study. No study specific information for the EU_longevity consortium was available. 
Causes of death were not available in the look-up cohorts.
Table 1. General Characteristics of Discovery Cohorts
N
Age at DNA Draw
Women (%) Alive (%)
Cause of Death (%)*
Mean (SD) CVD Cancer Other Unknown
Rotterdam Study 1 (RS1) 90+ cases 899 82.3 (6.1) 79.0 23.6 31.4 7.9 60.7 0.0
Comparison 1,192 66.5 (5.6) 41.3 0.0 32.2 40.1 27.7 0.0
Rotterdam Study 2 (RS2) 90+ cases 69 86.0 (6.2) 60.9 69.6 33.3 14.3 52.4 0.0
Comparison 161 66.0 (3.3) 37.3 0.0 23.6 50.3 26.1 0.0
Study of Osteoporotic  
Fractures (SOF)†
90+ cases 1,720 72.7(5.8) 100.0 54.4 16.8 3.6 21.5 0.0
Comparison 124 69.6 (3.4) 100.0 0.0 37.9 28.2 33.9 0.0
Cardiovascular Health  
Study (CHS)
90+ cases 791 77.7 (5.0) 62.3 41.7 51.5 17.3 30.6 0.6
Comparison 560 69.5 (3.0) 53.2 0.0 33.6 39.3 27.0 0.2
Osteoporotic Fractures  
in Men Study (MrOS)‡
90+ cases 670 83.0 (3.4) 0.0 43.6 19.9 6.9 21.8 3.1
Comparison 502 70.8 (3.4) 0.0 0.0 29.3 38.8 31.7 0.2
Framingham Heart  
Study (FHS)
90+ cases 320 86.7 (4.3) 66.9 0.0 24.1 11.6 51.9 12.5
Comparison 484 65.4 (7.3) 34.3 0.0 24.6 43.8 25.2 6.4
Health and Retirement  
Study (HRS)
90+ cases 384 89.3 (3.1) 67.5 68.5 3.0 15.0 12.6 69.5
Comparison 401 69.4 (6.2) 45.6 0.0 12.1 10.1 16.2 61.6
Age, Gene/Environment 
SusceptibilityReykjavik  
Study (AGES)
90+ cases 541 84.9 (2.8) 61.2 65.1 27.3 8.4 16.2 48.1
Comparison 145 72.8 (3.0) 49.0 0.0 28.2 35.5 18.4 18.0
Religious Orders Study and Rush  
Memory and Aging Project (RADC)
90+ cases 468 85.9 (5.0) 75.2 40.0 0.0 0.0 0.0 100.0
Comparison 78 70.2 (3.4) 48.7 0.0 0.0 0.0 0.0 100.0
Invecchiare nel Chianti  
(InCHIANTI)
90+ cases 101 92.8 (2.9) 72.3 70.3 8.9 3.0 7.9 80.2
Comparison 75 72.8 (4.0) 36.0 0.0 6.7 20.0 4.0 69.3
Baltimore Longitudinal Study of  
Ageing (BLSA)
90+ cases 128 91.42 (3.96) 49.2 50.0 4.7 1.0 3.0 91.4
Comparison 42 69.14 (6.25) 26.2 0.0 9.5 19.0 2.3 69.1
Notes: *In cases the % of all deaths is reported.
† In SOF, the vital status is not known for all individuals.
‡ In MrOS, the vital status is not known for all individuals.
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rs10457180) are both intronic, which are not present in 
ZNF286B. Therefore, we believe our results are not affected 
by this phenomenon.
Although our look-up for both CADM2 and GRIK2 did 
not show consistent associations, these genes are interesting 
candidate genes for longevity. Both genes are involved in 
neuronal pathways, in particular in neuron cell–cell adhe-
sion and regulation of glutamatergic synaptic transmission 
(www.genenetworks.nl). Neuronal pathways have been 
implicated earlier in all-cause mortality in a formal path-
way analysis (36).
We did not replicate other earlier reported associations 
with longevity, except for FOXO3 and APOE. Although 
many attempts to unravel the genetic contribution to the 
longevity phenotype have been undertaken, it has proven 
difficult to find robust associations (26). Genome-wide 
association studies have identified the genetic architecture 
of many complex traits with great success, even when the 
heritability of the trait is modest, as is the case for longevity. 
Yet the longevity phenotype remains elusive to uncovering 
new genetic associations.
As with any chosen methodology GWAS has its pitfalls. 
The most obvious pitfall of a GWAS is the low p value of 
significance required to call a variant significantly asso-
ciated. There are many potential sources of Type I and II 
errors in GWAS, including case–control misclassification, 
nongenetic covariates, and population stratification, which 
can only partly be accounted for in the design of the study 
(37). We have used the standard approach of considering p 
values < 5 ×10−8 as significant to prevent false positive find-
ings. As a result, we accept the presence of false negative 
findings. Recently, we have shown that the number of false 
positive findings increases exponentially when higher p val-
ues are used in GWAS setting, further justifying the use of 
a stringent cut-off (38). We do not believe that case–control 
misclassification is a big issue in our study as we have very 
clear cut-offs for being included as a case (≥90 years) or 
control (deceased between 55 and 80 years). The poten-
tial influence of nongenetic covariates is more difficult to 
ascertain. However, these are assumed to be independent of 
genotypes and are therefore unlikely to be confounders. In 
addition, it has been shown that the power of meta-analysis 
is not optimal for SNPs with small to modest effect sizes 
(39). However, it is common practice in GWAS to perform 
large-scale meta-analyses as the sample size required to 
detect variants at such low p values is not sufficient in any 
one study. Increasing the sample size of the current study 
may help identify new variants.
There are several potential explanations for why lon-
gevity has proven difficult to dissect genetically. First, the 
longevity phenotype simply could be too complex and 
heterogeneous for successful identification of longevity 
genes. Achieving longevity may require a great number of 
“protective” genes all with small effects (20). Although in 
highly heritable traits, like height, genes with very small 
effects have been uncovered, in a trait like longevity it may 
be challenging to identify individual genetic variants given 
the numbers of available genotyped individuals reach-
ing longevity. In addition, the complexity of the longevity 
phenotype is made more challenging due to its interaction 
with a number of age-related diseases, that is, cancer, car-
diovascular disease, and dementia, all of which have inde-
pendent genetic risk variants. Although it has been shown 
that currently identified variants for age-related diseases do 
not strongly associate with longevity (40), suggesting that 
there are longevity-specific variants remaining to be discov-
ered, this genetic and phenotypic heterogeneity of longevity 
makes it very challenging to identify genetic variants for 
longevity.
Using biomarkers that explain (a part of) longevity might 
be a more fruitful pursuit for finding associations with lon-
gevity itself. Unfortunately, no good biomarkers of aging 
currently exist, although many have been proposed (41). 
Telomere length, a marker of senescence, could be an inter-
esting biomarker of aging and, GWAS have already proven 
successful in identifying genes for this trait (42). An alter-
native approach could be the development of novel phe-
notypes like the healthy aging index, which incorporates 
information across physiologic systems and predicts mor-
tality better than age itself (43).
The second potential reason for not finding any genome-
wide significant associations with the longevity phenotype 
is that GWAS targets common variants. As longevity in the 
general population is quite rare, but common in specific 
long-lived families, it could be that rare variants, rather than 
common variants are involved in the longevity phenotype 
(44). Such variants are not likely to be picked up in GWAS, 
but may be uncovered with rare variant association analysis, 
which requires sequencing technology (45).
Another avenue that deserves consideration for future 
studies is the identification of joint genetic effects (epista-
sis) (46). Epistasis has been demonstrated to be an important 
contributor to age-related diseases such as cardiovascular 
disease (47). Methods for identifying epistasis are improv-
ing and becoming feasible for genome-wide studies (48).
Finally, it is possible that epigenetic changes could influ-
ence the expression of genetic variations leading to longevity. 
Epigenetic modifications such as DNA methylation and his-
tone modification are essential for development and differen-
tiation, but can also arise later in life (49). Age-related changes 
in DNA methylation have been implicated in senescence and 
longevity (50). Such changes may be a major contributor 
to longevity that might make it difficult to find associations 
with common genetic variants. A known phenomenon in lon-
gevity is that the majority of individuals reaching longevity 
are female. Whether this has a genetic or epigenetic basis is 
unknown and should be investigated in future studies.
A limitation of our phenotype is our definition of longev-
ity, namely, living to age ≥90 years may not be “extreme” 
enough as a case definition. We considered more extreme 
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longevity cut-offs, including centenarian status; however, 
we found that the sample size for such currently was not 
enough to have sufficient power to detect association in 
GWAS. Similarly, the definition of dying before 80 years 
might be too liberal for the definition of controls since they 
survived far beyond the average life expectancy for their 
respective birth cohort. Furthermore, more extreme cut-offs 
would have resulted in a too small sample size for GWAS.
In conclusion, we confirmed the association of FOXO3 
and APOE with longevity, but did not find any new associa-
tions, aside from the suggestive evidence for CADM2 and 
GRIK2. Notably, variants in neuronal pathway genes were 
confirmed to play a role in longevity. Future genetic studies 
should consider: (i) using more extreme age definitions for 
longevity, (ii) performing rare variant association analyses, 
(iii) analyzing epistasis, (iv) exploring epigenetic changes 
associated with longevity, (v) sex-specific analysis, and 
(vi) increasing the sample sizes of both cases and controls.
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